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Abstract 
Background 
Precision medicine has been adopted in a range of clinical settings where omics data 
have led to greater characterisation of disease and stratification of patients into sub-
categories of phenotypes and pathologies. However, in orthopaedics, precision 
medicine lags behind other disciplines such as cancer. 
Joint registries have now amassed a huge body of data pertaining to implant 
performance which can be broken down into performance statistics for different material 
types in different cohorts of patients. The National Joint Registry of England, Wales and 
Northern Ireland (NJR) is now one of the largest data sets available. Other registries 
such as those from Sweden and Australia however contain longer follow up. Together 
these registries can provide a wealth of informative for the orthopaedics community 
when considering which implant to give to any particular patient. 
Questions/purpose 
We aim to explore the benefits of combining multiple large data streams including joint 
registries, published data on OA pathogeneis and pathology, and data concerning 
performance of each implant material combination in terms of biocompatibility. We 
believe that taking into account the wealth of information from each of these streams will 
provide the most comprehensive overview of implant performance and allow surgeons 
to make more informed choices about which implant should be used in which patient.  
Methods 
Data from three joint registries were combined with established literature to highlight the 
heterogeneity of OA disease and the different clinical outcomes following arthroplasty 
with a range of material types. 
Results 
However, joint registries only go so far and don’t consider differences in arthritis 
presentation or underlying drivers of pathology. It is inappropriate to consider all OA 
patients to have the same pathology and this is reflected in the large body of work which 
has now identified hallmarks of OA and how they affect different patient populations. 
Equally, just as OA is a heterogeneous disease, there are disparate responses to wear 
debris from different material combinations used in joint replacement surgery. This has 
been highlighted by recent high-profile scrutiny of early failure of metal-on-metal total 
hip replacement (THR) implants. Indeed our own work has highlighted the difference in 
response to implant debris from metal-on-metal implants. 
Conclusions 
Bringing together data from joint registries, biomarker analysis, phenotyping of OA 
patients and knowledge of how different patients respond to implant debris will lead to a 
truly personalised approach to treating OA patients, ensuring that the correct implant is 
given to the correct patient at the correct time. 
 
 
 
 
Introduction 
The increasing use of joint registry data to guide surgeons in their choice of implant 
provides a huge opportunity to improve the care that patients receive. The use of these 
data to identify implants with higher failure rates, such as large bearing metal-on-metal 
devices, has the potential to significantly reduce harm to our patients. However, the 
temptation to extrapolate findings within large datasets in an effort to come up with a 
single “one size fits all” solution must be used with caution.  
Over the last few years there has been an explosion in the use of what is referred to as 
precision (or personalised) medicine in other areas of healthcare.  This model of patient 
care moves away from the “one size fits all” model of healthcare delivery and provides 
personalised or precision treatment based on the individual. For example, cancer 
treatment has been revolutionised by the use of biomarkers to stratify patients into 
responders and non-responders for specific pharmacological agents. This has been 
particularly highlighted by AstraZeneca’s development and study of Iressa (Gefitinib) for 
patients with non-small cell lung cancer. This drug targets the epidermal growth factor 
receptor (EGFR) and when administered to a large mixed cohort of patients was shown 
to have poor efficacy. However, 10% of the patient cohort had a mutation in their EGFR 
and these patients responded well to treatment[1]. This precision approach therefore 
improves patient care and reduces healthcare costs, since those patients who it is 
predicted will receive either no benefit or at worst a detrimental effect, are not 
administered a costly treatment regimen. In essence, providing the right treatment to the 
right patient. 
Within this review we explore the use of joint registry data in the decision making 
process with regards to its usefulness and its limitations in selecting the correct bearing 
for our patients. We also review the evidence that suggests OA patients are a 
heterogeneous group, and consider the potential for biomarker analysis to provide 
precision medicine which then assists the clinician in making a more informed choice in 
selecting the right implant for the right patient. 
 
 
Methods: 
Data from three large joint registries, Swedish Hip Arthroplasty Register, National Joint 
Registry of England, Wales and Northern Ireland and the Australian Orthopaedic 
Association National Joint Replacement Registry regarding implant performance were 
collated. Pubmed literature searches were used to identify articles pertaining to different 
presentations of OA with regards to environmental and demographic factors which 
affect OA pathology, thus demonstrating the heterogeneity of the disease. In order to 
link factors governing OA pathology with implant failure, literature which explore the 
causal factors which contribute to implant failure were also highlighted.  
 
 
International Joint Registries 
When considering joint registry data it is difficult to ignore the contribution from the 
Swedish Hip Arthroplasty Register[2]. However the use of different bearing surfaces is 
relatively limited with the large majority of hip arthroplasty utilising the combination of 
metal femoral heads with a polyethylene acetabulum. Over the last decade there has 
been a gradual migration to the use of cross linked or modified polyethylene. With the 
most recent report the revision rates of the cross linked polyethylene was found be 
significantly less than that of conventional polyethylene. However, when confounding 
factors such as age, gender, femoral head size and acetabular design were considered, 
the difference failed to reach significance. Data for other bearings in this registry are 
very limited and, therefore, it is difficult make comparisons between multiple bearing 
surfaces. The 2014 report from the National Joint Registry for England, Wales and 
Northern Ireland (NJR)[3] contained outcome data on over 620,400 hip replacements 
with a maximum follow-up of 10.75 years. The report provides a wealth of data on the 
outcome and usage of hip replacements. When the registry was started in 2003, 
cemented hip arthroplasty was the most common fixation modality. However, more 
recently the use of uncemented hip replacements has become more common and is 
now the main method of fixation of total hip replacements (Figure 1). The use of hybrid 
fixation had remained relatively static over the years but has increased slightly, most 
likely due to outcome data published by the NJR supporting the use of hybrid fixation. 
The use of different bearing combinations in cemented hip replacement is relatively 
limited with 90% of the bearing articulations composed of a metal femoral head and a 
polyethylene acetabular component (Figure 2). The type of bearing surface used in the 
uncemented hip replacement is much more varied (Figure 3). When the registry was 
initiated, the two most common bearing options were that of a metal femoral head on a 
polyethylene liner and the use of a ceramic head on a polyethylene liner. Between 2003 
and present, the usage of the different bearing combinations has quite dramatically 
changed. The usage of a metal-on-metal combination increased to its height in 2007 
and then decreased following this due to the concerns with respect to metal particle 
debris. The use of a ceramic-on-ceramic bearings were significantly increased in their 
usage to a peak in 2011. One explanation of this may have been that ceramic-on-
ceramic bearings were marketed as an alternative to metal-on-metal bearings following 
the decline in use of the latter. Ceramic femoral head on a polyethylene liner usage 
decreased between 2003 and 2008 but have now gradually increased in their usage, 
possibly driven by the outcome data produced by the NJR. The use of metal-on-
polyethylene has remained relatively constant and in 2013 was still the most common 
bearing option for uncemented hip arthroplasty. The NJR provides a wealth of 
information on the cumulative probability of revision for different bearing combinations, 
fixation type, age and gender. Overall the cumulative revision rates for the cemented 
group appear to show that ceramic-on-polyethylene may have a slight advantage over 
that of metal-on-polyethylene (Figure 4). Within the uncemented group, the Kaplan 
Meier estimates for cumulative probability of revision show that the metal-on-
polyethylene, ceramic-on-polyethylene and ceramic-on-ceramic combinations appear to 
be very tightly clustered with the ceramic-on-polyethylene appearing to show a slight 
improvement in revision rates (Figure 5). One of the present limitations of this registry is 
that the types of polyethylene are presently not stratified by types of treatment used. 
This is a concern as other registries have shown a significant advantage of the cross 
linked or modified polyethylene. 
The Australian Orthopaedic Association National Joint Replacement Registry 
(AOANJRR)[4] was started in 1999 and the annual report published in 2014 contains 
data on 280,522 primary total hip replacements. The report provides the percentage 
revision rates of an array of different bearing surfaces. The combination of a 
ceramicised metal femoral head with a cross-linked polyethylene liner has consistently 
shown the lowest revision rates (Figure 6). The use of a metal femoral head or a 
ceramic femoral head combined with a cross linked polyethylene liner has also shown 
low revision rates. However, the combination of a ceramic-on-ceramic bearing surface 
surprisingly shows a slightly higher revision rate than that of either of the other three 
combinations. The AOANJRR report clearly shows the significant reduction in revision 
rates when using cross linked polyethylene when compared to non cross-linked 
polyethylene (Figure 7). This reduction in revision rate appears to be explained by the 
reduction in revision for loosening/lysis and a reduction in the number of revisions 
performed for dislocation. The reduction in dislocation rate would be partially explained 
by the increased confidence in the use of larger head sizes with the cross linked 
polyethylene. 
 
Discussion 
The wealth of information contained within the national joint registries on the outcome of 
different parameters in hip arthroplasty has the potential to drive significant change in 
the way that we deliver care. However, the use of these data to inform guidance and 
policy needs to be treated with caution. This can be shown in the NJR in that the 
reported revision rates over the years since the commencement of the registry have 
gradually increased (Figure 8). One may hypothesise that this is due to the fact that 
more hips are being revised. However, one alternative hypothesis may be that as the 
registry has become embedded into clinical practice, the robustness of the reporting of 
revision operations may have improved. This potential bias would particularly favour 
those implant combinations that were used at the inception of the registry and 
detrimental to those introduced more recently. This potential bias would appear to 
potentially favour cemented fixation with a metal or ceramic femoral head on a 
polyethylene liner. 
When considering how to interpret the outcomes provided by the joint registries one key 
aspect that we must not ignore is that of personalised or precision medicine. There is 
significant pressure when provided with vast data sets to try to provide a “one size fits 
all” solution. We must however be cognisant of developments being made in other 
areas of medicine. Surgeons will often personalise their choice of implant depending on 
patient characteristics. An example would be that of bone quality and the decision to 
use a cemented or uncemented femoral component. Good bone quality and a very 
narrow femoral canal is well suited to a tapered uncemented stem whereas a porotic 
femur with a very large femoral canal would be more suited to a cemented femoral 
component. A step further from this type of personalised care is that of precision 
medicine which includes the use of biomarkers to stratify patients into different patient 
groups. 
Our understanding of OA and the factors which are involved in pathogenesis has 
progressed beyond considering this to be a wear and tear disease, and has led to a 
wealth of information pertaining to biomarkers being collected from a multitude of 
patients. These patients reveal further information regarding the prevalence of each 
biomarker in different patient cohorts. Therefore, it may be prudent to marry these data 
to those contained in joint registries to further stratify patients and inform surgeons as to 
the correct implant for the correct patient at the correct time. 
OA is a heterogeneous disease 
With the majority of hip arthroplasty performed for osteoarthritis it is increasingly 
recognised that OA is a heterogeneous disease[5, 6].  Multiple tissues within the joint 
are now implicated in pathogenesis of OA, including not just the cartilage but also the 
subchondral bone, synovium and adipose tissue, and the involvement of each of these 
tissues in the pathogenesis may be dependent on the particular patient[7]. For example, 
the association between increased adiposity and OA risk has been reported to be 
greater in females[8]. 
Critically, the heterogeneous nature of OA can also be observed in pre-operative x-ray 
radiographs, where the presence of osteophytes, suggesting the involvement of 
abnormal subchondral bone remodelling, is present in some patients but not others. 
Together with variations in the degree of joint space narrowing, patients undergoing 
joint replacement surgery vary from Kellgren Lawrence (KL) grade 1 to KL grade 4[9], 
indicating great diversity in the radiological features of OA across patients[10].    
Given that inflammation is now increasingly recognised as a key contributor to OA joint 
pathology, it is significant that MRI and histopathological studies show that the degree 
of synovitis (synovial inflammation) varies between OA patients[11].  Notably, our 
preliminary studies suggest that those OA patients who are obese exhibit a more 
“inflammatory” phenotype than those patients who are of normal-weight.  Indeed, 
inflammation associated with the synovium and tissues adjacent to the synovium is 
more prevalent in obese patients with OA, compared to normal weight OA patients[12]. 
This increase in inflammation in obese individuals can be partly attributed to our 
understanding now that adipose tissue is an endocrine organ, capable of releasing 
cytokines (termed adipokines), which can mediate pro-inflammatory and ultimately 
pathological effects on the joint tissues.   
The functional role of particular adipokines in OA pathology is still being investigated but 
current literature suggests that the adipokines leptin, resistin and visfatin all contribute 
to inflammation in the joint[13-16]. Importantly however, differences in both the 
functional effects in the joint and/or expression of these adipokines in serum and in joint 
tissues have been reported to be dependent on BMI and gender[15].    
This evidence demonstrates that cellular activation varies between OA patients. This 
naturally leads OA presentation to differ between patients giving rise to a 
heterogeneous OA phenotype. As will be discussed below, activation of immune cells 
is, at least in part, responsible for the failure of some arthroplasties in some patients. 
Patients whose OA phenotype is particularly inflammatory may, therefore, not be suited 
to some implant types which are known to invoke an inflammatory response.  
OA joint implants:  One size does not fit all 
One particular area of concern in the arthroplasty domain has been the skill of 
implantation and the familiarity of implants to the surgeon. There is, therefore, a balance 
between the personalisation of implant selection to best suit the patient and the number 
of different implants that the surgeon uses to ensure that they remain sufficiently skilled 
with each device. 
In the same way that OA is a heterogeneous disease with different factors affecting 
disease presentation and progression, the biological response of individuals to implant 
materials is also diverse. 
The cumulative percentage probability of first revision at 10 years is 2-4% for bearing 
combination such as metal or ceramic on polyethylene and ceramic on ceramic. The 
exception to this is metal-on-metal which has a cumulative risk percentage of 22% at 10 
years[17]. This discrepancy in longevity between metal-on-metal and other implants 
was highlighted by Smith et al (2012)[17].  Despite metal-on-metal being predicted to be 
hard-wearing, there is a 50% greater risk of MoM failure compared to that of metal-on-
polyethylene 2-years post-surgery. The reason for this high risk of failure is only now 
beginning to be understood.   However, such has been the fallout from the revelation 
that MoM implants are negatively impacting on the patients who receive them, a large 
body of work has been undertaken to understand the reason for patients’ adverse 
reactions to different material types at the molecular level[18-21]. This work includes 
examination of components of the implant such as the taper junction and acetabular cup 
interface[22, 23]. 
One particular area of research is to examine the way in which the patient’s immune 
system responds to the burden of challenge from wear debris. Importantly, it is now 
accepted that CoCrMo alloy debris elicits an immune response which involves both 
macrophages and T cells[24, 25], along with an increase in proinflammatory cytokine 
production[25]. Furthermore, metal wear debris become coated in protein from intra-
tissue fluids and serum and it is postulated that this coating, which would include 
immunomodulatory proteins such as complement, could be used by macrophages to 
recognise and internalise non-biological materials[26]. 
 
Indeed, we have recently performed our own study to investigate the role of the immune 
system in responding to wear debris from metal-on-metal implants, and the resulting 
inflammatory response. Our findings show that individuals will produce profoundly 
contrasting systemic biological responses to the presence of wear debris from joint 
implants and that these transcend the macrophage to implicate other lymphocytes such 
as T cells[25]. Additionally, individuals will produce different cytokine profiles in 
response to wear debris, and these profiles could be used to prognostically determine 
the risk of using a particular material type in any individual patient as well as in the 
treatment of patients who are showing adverse effects from already receiving an 
inappropriate implant. 
 
Lessons from metal-on-metal THR implants have demonstrated that the preference of 
the surgeon alone should not be a driver in the determination of treatment for all 
patients. Vast quantities of data are deposited in joint registries regarding the 
performance of different implants. These data, coupled with the determination of 
immune tolerance towards implant materials and biomarker studies to stratify the 
heterogenic OA patient population, could pave the way for a truly personalised 
approach to determining which implant a specific patient should be given. 
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Figure 1 Temporal changes in percentages of each fixation method used in primary hip replacements (From The 2014 report 
from the National Joint Registry for England, Wales and Northern Ireland, Figure 3.1) 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Percentage changes of each bearing surface used in primary hip replacements (From The 2014 report from the 
National Joint Registry for England, Wales and Northern Ireland, Figure 3.2a) 
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Figure 3  Percentage change in bearing surface used in uncemented total hip replacement (From The 2014 report from the 
National Joint Registry for England, Wales and Northern Ireland, Figure 3.2b) 
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Figure 4 Cumulative probability of revision (Kaplan-Meier estimates) for cemented hips with different bearing surfaces (From 
The 2014 report from the National Joint Registry for England, Wales and Northern Ireland, Figure 3.4) 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 Cumulative probability of revision (Kaplan-Meier estimates) for uncemented hips with different bearing surfaces (From 
The 2014 report from the National Joint Registry for England, Wales and Northern Ireland, Figure 3.5) 
  
 
 
 
 
  
Figure 6 Cumulative percent revision of primary total conventional hip replacement by type of polyethylene (primary 
diagnosisOA) (From The Australian Orthopaedic Association National Joint Replacement Registry, Figure HT22) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 7 Cumulative incidence revision diagnosis of primary total conventional hip replacement by type of polyethylene 
(primary diagnosis OA) (From The Australian Orthopaedic Association National Joint Replacement Registry, Figure HT23). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 8 Temporal changes in revision rates: Kaplan-Meier estimates of cumulative percentage probability of revision for each 
year of primary operation (From The 2014 report from the National Joint Registry for England, Wales and Northern Ireland, 
Figure 3.3a) 
 
 
